NAD Augmentation in Diabetes Kidney Disease
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age30+
SponsorBrigham and Women's Hospital
About this trial
A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily.
Eligibility criteria
Qualifiers
A man or a postmenopausal woman (complete cessation of menses for one or more years and /or FSH > 20 U/L), 30 years or older
Self-report of type 1 or type 2 diabetes plus the use of a prescribed medication.
ICD-10 code for type 1 or type 2 diabetes plus current use of a medication in the electronic medical record.
HbA1c >6.4%; or 2 fasting glucose > 125 mg/dL
Disqualifiers
Fasting morning UACR > 5,000 mg/ g creatinine
Has AST or ALT > 3 times the upper limit of normal
eGFR < 25 mL/ min / 1.73 m2
Hematocrit < 0.34 or > 0.50 L/L
Trial design
Treatments tested in this trial
- Investigational Product - MIB 626
- Placebo
Treatment groups
156 Participants
are divided into 2 treatment groupsSponsors and collaborators
Brigham and Women's Hospital
Lead sponsor
Boston Medical Center
Collaborator
Source ClinicalTrials.gov